About Ascelia
Ascelia is a company based in Malmo (Sweden) founded in 2000. Ascelia has raised $6.92 million across 2 funding rounds. Ascelia offers products and services including Orviglance and Oncoral. Ascelia operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter Malmo, Sweden
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ascelia Pharma Ab
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$6.92 M (USD)
in 2 rounds
-
Latest Funding Round
$23.38 M (USD), Post-IPO
Mar 22, 2021
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ascelia
Ascelia offers a comprehensive portfolio of products and services, including Orviglance and Oncoral.
Imaging agent for detecting liver metastases in cancer
Treatment option for gastric cancer patients
People of Ascelia
Unlock access to complete
Funding Insights of Ascelia
Ascelia has successfully raised a total of $6.92M across 2 strategic funding rounds. The most recent funding activity was a Post-IPO round of $23.38 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Ascelia
Investment portfolio details for Ascelia
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Ascelia
Detailed financials for Ascelia
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ascelia Comparisons
Peer comparison for Ascelia
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ascelia
Ascelia operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
Detailed competitors of Ascelia
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ascelia
Complete news archive for Ascelia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ascelia
Ascelia was founded in 2000 and raised its 1st funding round 18 years after it was founded.
Ascelia is headquartered in Malmo, Sweden.
Ascelia is a funded company, having raised a total of $6.92M across 2 funding rounds to date.
Ascelia was founded in 2000 in Malmo, Sweden, within the pharmaceutical sector. Drug candidates targeting diseases with unmet clinical needs are developed, focusing on orphan indications. Operations center on clinical-stage products, including Mangoral, a contrast agent prepared for phase 3 trials to identify liver metastases via MRI, and Oncoral, an oral chemotherapeutic in phase 2 for advanced gastric cancer.
Ascelia's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Ascelia offers Orviglance and Oncoral.